用SGLT-2抑制剂治疗的患者管理尿生殖系统不良影响的临床建议:多学科专家共识
Juan J Gorgojo-Martínez1, José L Górriz2, Ana Cebrián-Cuenca3
1Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, Alcorcón, 28922 Madrid, Spain.
Journal of clinical medicine
|November 9, 2024
概括
停止使用SGLT-2抑制剂 (SGLT-2is) 治疗生殖尿道事件的风险是失去心脏和脏的益处. 预防策略和及时管理,而不是常规停止,是维持治疗疗效的关键.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- SGLT-2 抑制剂 (SGLT-2is) 是对2型糖尿病,CKD和心力衰竭的重要一线治疗方法.
- 这些药物显著降低心血管和脏风险.
- 生殖尿路 (GU) 的不良事件 (AEs) 可能导致停止治疗,危及这些益处.
研究的目的:
- 审查与SGLT-2i治疗相关的GU AEs的证据.
- 提供关于预防和管理GUAE的指导.
- 通过避免不必要的停药,强调保持心脏脏的益处.
主要方法:
- 多学科专家小组对现有证据的审查.
- 专注于生殖器真菌感染,尿道感染和LUTS.
- 考虑一般和高风险人群 (移植接受者).
主要成果:
- 永久停药SGLT-2is导致心脏和脏的好处的快速丧失.
- 预防策略,包括启动前的风险评估,至关重要.
- 大多数GU感染是轻度/中度的,并且在不停止治疗的情况下对标准治疗有反应.
结论:
- 不建议对GUAE进行SGLT-2is的常规停用.
- 立即恢复SGLT-2i治疗,除非存在禁忌.
- 通过管理,而不是停止,GU AEs来保护心脏和脏的益处.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Oral Hypoglycemic Agents: Sulfonylureas
192
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
192
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141


